menu
    • menu
    [{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"XOPH","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Undisclosed","graph2":"Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Health & Services \/ Undisclosed"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Steve Yoelin M.D. Medical Associates, Inc.","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Steve Yoelin M.D. Medical Associates, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steve Yoelin M.D. Medical Associates, Inc. \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Steve Yoelin M.D. Medical Associates, Inc. \/ Allergan"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BYM338","moa":"Activin receptor type-2B","graph1":"Undisclosed","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"BYM338","moa":"Activin receptor type-2B","graph1":"Undisclosed","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alfa","moa":"ALPI","graph1":"Undisclosed","graph2":"Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ FGK Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"AM-Pharma \/ FGK Clinical Research"},{"orgOrder":0,"company":"ZandA Technologies, llc","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Undisclosed","graph2":"Phase II","graph3":"ZandA Technologies, llc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZandA Technologies, llc \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"ZandA Technologies, llc \/ KGK Science"},{"orgOrder":0,"company":"Chinese University of Hong Kong","sponsor":"Sugardown Company Limited","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HONG KONG","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BTI320","moa":"AMY1A\/MGAM\/Peptidases","graph1":"Undisclosed","graph2":"Phase II","graph3":"Chinese University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese University of Hong Kong \/ Sugardown Company Limited","highestDevelopmentStatusID":"8","companyTruncated":"Chinese University of Hong Kong \/ Sugardown Company Limited"},{"orgOrder":0,"company":"AbViro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbViro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbViro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbViro \/ Undisclosed"},{"orgOrder":0,"company":"AbViro","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbViro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbViro \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"AbViro \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Science Valley Research Institute","sponsor":"Stin Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Oxandrolone","moa":"Androgen Receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Science Valley Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Science Valley Research Institute \/ Stin Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Science Valley Research Institute \/ Stin Pharma"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansa Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase II","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Cyathus Exquirere Pharmaforschungsgmbh","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cyathus Exquirere Pharmaforschungsgmbh","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cyathus Exquirere Pharmaforschungsgmbh \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyathus Exquirere Pharmaforschungsgmbh \/ Undisclosed"},{"orgOrder":0,"company":"Norton Healthcare","sponsor":"University of Kentucky","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Norton Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norton Healthcare \/ University of Kentucky","highestDevelopmentStatusID":"8","companyTruncated":"Norton Healthcare \/ University of Kentucky"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Auriclosene","moa":"Bacterial biofilm","graph1":"Undisclosed","graph2":"Phase II","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"NVC-422","moa":"Bacterial cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Catheter","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"National University Health System, Singapore","sponsor":"National University of Singapore | Health Promotion Board, Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SINGAPORE","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Undisclosed","graph2":"Phase II","graph3":"National University Health System, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National University Health System, Singapore \/ National University of Singapore | Health Promotion Board, Singapore","highestDevelopmentStatusID":"8","companyTruncated":"National University Health System, Singapore \/ National University of Singapore | Health Promotion Board, Singapore"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"The Hospital for Sick Children \/ World Health Organization","highestDevelopmentStatusID":"8","companyTruncated":"The Hospital for Sick Children \/ World Health Organization"},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Anti-Bcma Car-T Cell","moa":"BCMA receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The First Affiliated Hospital of Soochow University \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","highestDevelopmentStatusID":"8","companyTruncated":"The First Affiliated Hospital of Soochow University \/ Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd"},{"orgOrder":0,"company":"AOP Orphan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AOP200704","moa":"Beta-1 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"AOP Orphan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AOP Orphan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AOP Orphan \/ Undisclosed"},{"orgOrder":0,"company":"Sundeep Khosla, M.D.","sponsor":"Columbia University | MaineHealth | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atenolol","moa":"Beta-1 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sundeep Khosla, M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sundeep Khosla, M.D. \/ Columbia University | MaineHealth | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Sundeep Khosla, M.D. \/ Columbia University | MaineHealth | University of California, San Francisco"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Salmeterol Xinafoate","moa":"Beta-2 adrenergic receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"American Academy of Pediatrics | Academic Pediatric Association","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Undisclosed","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ American Academy of Pediatrics | Academic Pediatric Association","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ American Academy of Pediatrics | Academic Pediatric Association"},{"orgOrder":0,"company":"Bailing Group Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Tang Ning Tonglu","moa":"Blood glucose level","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bailing Group Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bailing Group Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bailing Group Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bailing Group Pharmaceutical","sponsor":"China-Japan Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Tang Ning Tonglu","moa":"Blood glucose level","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bailing Group Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bailing Group Pharmaceutical \/ China-Japan Friendship Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Bailing Group Pharmaceutical \/ China-Japan Friendship Hospital"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Inebilizumab","moa":"B-lymphocyte antigen CD19","graph1":"Undisclosed","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Clinical Trials in Organ Transplantation in Children | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation in Children | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation in Children | Rho, Inc"},{"orgOrder":0,"company":"University of Utah","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"223-Ra Radium-223 Dichloride","moa":"Bone resorption","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"University of Utah \/ Bayer AG"},{"orgOrder":0,"company":"Yale University","sponsor":"Biopharmaceutical Research Company | Bloom Labs Cannabis Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Biopharmaceutical Research Company | Bloom Labs Cannabis Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Biopharmaceutical Research Company | Bloom Labs Cannabis Solutions"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Chlorhexidine","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Medline Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"Medline Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medline Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medline Industries \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ University of Pennsylvania","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ University of Pennsylvania"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NewAmsterdam Pharma \/ Pharma Medica Research","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ Pharma Medica Research"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Novum","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewAmsterdam Pharma \/ Novum","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ Novum"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewAmsterdam Pharma \/ Pharma Medica Research","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ Pharma Medica Research"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"MB Clinical Research and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obicetrapib","moa":"Cholesteryl ester transfer protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"NewAmsterdam Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NewAmsterdam Pharma \/ MB Clinical Research and Consulting","highestDevelopmentStatusID":"8","companyTruncated":"NewAmsterdam Pharma \/ MB Clinical Research and Consulting"},{"orgOrder":0,"company":"TAHO Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase II","graph3":"TAHO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"TAHO Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TAHO Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Bayer AG | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase II","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Bayer AG | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Bayer AG | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Insel Gruppe AG, University Hospital Bern","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Undisclosed","graph2":"Phase II","graph3":"Insel Gruppe AG, University Hospital Bern","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insel Gruppe AG, University Hospital Bern \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Insel Gruppe AG, University Hospital Bern \/ Bayer AG"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Undisclosed","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Undisclosed","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Sanofi"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Celecoxib","moa":"Cyclooxygenase-2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Children's Hospital of Philadelphia \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital of Philadelphia \/ Pfizer Inc"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Metyrapone","moa":"CYP11B1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayo Clinic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Osilodrostat Phosphate","moa":"Cytochrome P450 11B1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Recordati Rare Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Recordati Rare Diseases"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pulmatrix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pulmatrix \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Voriconazole","moa":"Cytochrome P450 51||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"ASP0113","moa":"Cytomegalovirus Deoxyribonucleic acid (CMV DNA)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Vical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"ASP0113","moa":"Cytomegalovirus Deoxyribonucleic acid (CMV DNA)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Vical","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Vical"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Ciraparantag Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Ciraparantag Holdings","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Ciraparantag Holdings"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mosnodenvir","moa":"Dengue||DENV NS3\/DENV NS4B","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mosnodenvir","moa":"Dengue||DENV NS3\/DENV NS4B","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nordic Pharma \/ Nutrasource","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Pharma \/ Nutrasource"},{"orgOrder":0,"company":"GCP-Service International","sponsor":"University Hospital, Bonn | University Hospital Muenster | University Hospital G\u00f6ttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Phase II","graph3":"GCP-Service International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"GCP-Service International \/ University Hospital, Bonn | University Hospital Muenster | University Hospital G\u00f6ttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp","highestDevelopmentStatusID":"8","companyTruncated":"GCP-Service International \/ University Hospital, Bonn | University Hospital Muenster | University Hospital G\u00f6ttingen | University Hospital Schleswig-Holstein | Charite University, Berlin, Germany | Wuerzburg University Hospital | Johannes Gutenberg University Mainz | University Hosp"},{"orgOrder":0,"company":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"Dipeptidyl peptidase IV","graph1":"Undisclosed","graph2":"Phase II","graph3":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Profil Institut f\u00fcr Stoffwechselforschung GmbH \/ Merck & Co"},{"orgOrder":0,"company":"University of Oxford","sponsor":"SBI Pharmaceuticals Co, Ltd. | George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Oxford \/ SBI Pharmaceuticals Co, Ltd. | George Clinical","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ SBI Pharmaceuticals Co, Ltd. | George Clinical"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"National Heart, Lung, and Blood Institute | National Jewish Health | University of Texas Health Science Center at Tyler | National Institute of Allergy and Infectious Diseases | University of Chicago | Temple University | University of South Florida","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oregon Health and Science University \/ National Heart, Lung, and Blood Institute | National Jewish Health | University of Texas Health Science Center at Tyler | National Institute of Allergy and Infectious Diseases | University of Chicago | Temple University | University of South Florida","highestDevelopmentStatusID":"8","companyTruncated":"Oregon Health and Science University \/ National Heart, Lung, and Blood Institute | National Jewish Health | University of Texas Health Science Center at Tyler | National Institute of Allergy and Infectious Diseases | University of Chicago | Temple University | University of South Florida"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"ASTX727","moa":"DNA [cytosine-5]-methyltransferase (DNMT)","graph1":"Undisclosed","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Peter MacCallum Cancer Centre","sponsor":"Movember Foundation | Prostate Cancer Research Alliance | US Department of Defense | Advanced Accelerator Applications | Australia Nuclear Science and Technology Organisation | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Austr","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"DNA | Glutamate carboxypeptidase II","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peter MacCallum Cancer Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peter MacCallum Cancer Centre \/ Movember Foundation | Prostate Cancer Research Alliance | US Department of Defense | Advanced Accelerator Applications | Australia Nuclear Science and Technology Organisation | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Austr","highestDevelopmentStatusID":"8","companyTruncated":"Peter MacCallum Cancer Centre \/ Movember Foundation | Prostate Cancer Research Alliance | US Department of Defense | Advanced Accelerator Applications | Australia Nuclear Science and Technology Organisation | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Austr"},{"orgOrder":0,"company":"Nordic Lymphoma Group","sponsor":"Mundipharma | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nordic Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Lymphoma Group \/ Mundipharma | Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Lymphoma Group \/ Mundipharma | Amgen Inc"},{"orgOrder":0,"company":"CellSight Technologies","sponsor":"Stanford University | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F AraG","moa":"DNA synthesis","graph1":"Undisclosed","graph2":"Phase II","graph3":"CellSight Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CellSight Technologies \/ Stanford University | Oregon Health and Science University","highestDevelopmentStatusID":"8","companyTruncated":"CellSight Technologies \/ Stanford University | Oregon Health and Science University"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Emalex Bioscience \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Covance"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Psyadon Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Psyadon Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Psyadon Pharma"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Icon Plc | Nuventra","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ecopipam","moa":"Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ Icon Plc | Nuventra","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Icon Plc | Nuventra"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Norprolac","moa":"Dopamine D2 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Undisclosed","graph2":"Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Domperidone Maleate","moa":"DRD2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Providence Health & Services","sponsor":"Earle A. Chiles Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Providence Health & Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Providence Health & Services \/ Earle A. Chiles Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Providence Health & Services \/ Earle A. Chiles Research Institute"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Undisclosed","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"60 Degrees Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tafenoquine","moa":"Electron transport complex III (Complex III)","graph1":"Undisclosed","graph2":"Phase II","graph3":"60 Degrees Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"60 Degrees Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"60 Degrees Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Nimotuzumab","moa":"Epidermal growth factor receptor erbB1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Latin American Cooperative Oncology Group","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lapatinib Ditosylate","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Latin American Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Latin American Cooperative Oncology Group \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Latin American Cooperative Oncology Group \/ GSK"},{"orgOrder":0,"company":"Martin Balslev J\u00f8rgensen","sponsor":"The Augustinus Foundation, Denmark. | Mental Health Services in the Capital Region, Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Martin Balslev J\u00f8rgensen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Martin Balslev J\u00f8rgensen \/ The Augustinus Foundation, Denmark. | Mental Health Services in the Capital Region, Denmark","highestDevelopmentStatusID":"8","companyTruncated":"Martin Balslev J\u00f8rgensen \/ The Augustinus Foundation, Denmark. | Mental Health Services in the Capital Region, Denmark"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Atossa Therapeutics \/ Karolinska Institutet","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Karolinska Institutet"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Atossa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Benaroya Research Institute","sponsor":"Virginia Mason Medical Center | Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Carbohydrate","year":"2012","type":"Inapplicable","leadProduct":"Lactulose","moa":"Evolved beta-galactosidase subunit alpha","graph1":"Undisclosed","graph2":"Phase II","graph3":"Benaroya Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benaroya Research Institute \/ Virginia Mason Medical Center | Cumberland Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Benaroya Research Institute \/ Virginia Mason Medical Center | Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Benaroya Research Institute","sponsor":"Virginia Mason Medical Center | Cumberland Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Carbohydrate","year":"2010","type":"Inapplicable","leadProduct":"Lactulose","moa":"Evolved beta-galactosidase subunit alpha","graph1":"Undisclosed","graph2":"Phase II","graph3":"Benaroya Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Benaroya Research Institute \/ Virginia Mason Medical Center | Cumberland Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Benaroya Research Institute \/ Virginia Mason Medical Center | Cumberland Pharmaceuticals"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"IW-6118","moa":"FAAH","graph1":"Undisclosed","graph2":"Phase II","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ironwood Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironwood Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DeNova Research","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Artiss Fibrin Sealant","moa":"Fibrin","graph1":"Undisclosed","graph2":"Phase II","graph3":"DeNova Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DeNova Research \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"DeNova Research \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Dexa Medica","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Dexa Medica"},{"orgOrder":0,"company":"Indonesia University","sponsor":"Dexa Medica","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DLBS1033","moa":"Fibrinolytic protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"Indonesia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indonesia University \/ Dexa Medica","highestDevelopmentStatusID":"8","companyTruncated":"Indonesia University \/ Dexa Medica"},{"orgOrder":0,"company":"Odense University Hospital","sponsor":"Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense | OPEN (The University of Southern Denmark) | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Odense University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Odense University Hospital \/ Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense | OPEN (The University of Southern Denmark) | Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Odense University Hospital \/ Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense | OPEN (The University of Southern Denmark) | Novo Nordisk"},{"orgOrder":0,"company":"Methodist Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Methodist Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Methodist Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Methodist Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Presatovir","moa":"Fusion glycoprotein F0","graph1":"Undisclosed","graph2":"Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Tosilate","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ABP-700","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"PAION UK LTD","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"PAION UK LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PAION UK LTD \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"PAION UK LTD \/ Premier Research Group"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"JNJ-64565111","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"JNJ-64565111","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"JNJ-64565111","moa":"Glucagon-like peptide 1 receptor | Glucagon receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Corticosteroid","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Universidad Nacional de Salta | Centro de Investigaci\u00f3n Veterinaria Tandil CIVETAN | Hospital de Pediatr\u00eda Prof Dr. Juan P. Garrahan | Universidad Nacional de Quilmes","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Undisclosed","graph2":"Phase II","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Elea Phoenix \/ Universidad Nacional de Salta | Centro de Investigaci\u00f3n Veterinaria Tandil CIVETAN | Hospital de Pediatr\u00eda Prof Dr. Juan P. Garrahan | Universidad Nacional de Quilmes","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorio Elea Phoenix \/ Universidad Nacional de Salta | Centro de Investigaci\u00f3n Veterinaria Tandil CIVETAN | Hospital de Pediatr\u00eda Prof Dr. Juan P. Garrahan | Universidad Nacional de Quilmes"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Proteonomix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Proteonomix","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Proteonomix"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Technologies","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Guanylate cyclase (GC)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cosmo Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cosmo Technologies \/ Cross Research S.A.","highestDevelopmentStatusID":"8","companyTruncated":"Cosmo Technologies \/ Cross Research S.A."},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Undisclosed","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"FORUM Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"FRM-0334","moa":"HDAC","graph1":"Undisclosed","graph2":"Phase II","graph3":"FORUM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FORUM Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"FORUM Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BMS-791325","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health Clinical Center","sponsor":"National Institute of Allergy and Infectious Diseases | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Asunaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institutes of Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health Clinical Center \/ National Institute of Allergy and Infectious Diseases | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health Clinical Center \/ National Institute of Allergy and Infectious Diseases | Bristol Myers Squibb"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paritaprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Simeprevir","moa":"Hepatitis C virus serine protease, NS3\/NS4A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cetirizine","moa":"Histamine H1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Vermont","sponsor":"Cancer and Leukemia Group B","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Loratadine","moa":"Histamine H1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Vermont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Vermont \/ Cancer and Leukemia Group B","highestDevelopmentStatusID":"8","companyTruncated":"University of Vermont \/ Cancer and Leukemia Group B"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"CONRAD | FHI 360 | United States Agency for International Development | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eastern Virginia Medical School \/ CONRAD | FHI 360 | United States Agency for International Development | Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Eastern Virginia Medical School \/ CONRAD | FHI 360 | United States Agency for International Development | Gilead Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Daprodustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Undisclosed","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GenSci048","moa":"IL-1?","graph1":"Undisclosed","graph2":"Phase II","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Neumedicines","sponsor":"U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NM-IL-12","moa":"IL-12 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Neumedicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumedicines \/ U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"8","companyTruncated":"Neumedicines \/ U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GSK1070806","moa":"IL-18","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase II","graph3":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"Chia Nan University of Pharmacy and Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase II","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"GenMont Biotech Incorporation \/ Chia Nan University of Pharmacy and Science","highestDevelopmentStatusID":"8","companyTruncated":"GenMont Biotech Incorporation \/ Chia Nan University of Pharmacy and Science"},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"Chia Nan University of Pharmacy and Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase II","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"GenMont Biotech Incorporation \/ Chia Nan University of Pharmacy and Science","highestDevelopmentStatusID":"8","companyTruncated":"GenMont Biotech Incorporation \/ Chia Nan University of Pharmacy and Science"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"Inosine-5'-monophosphate dehydrogenase (IMPDH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cedars-Sinai \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Cedars-Sinai \/ Sanofi"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Lithium Carbonate","moa":"Inositol-1(or 4)-monophosphatase 1 | Glycogen synthase kinase-3","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunnybrook Health Sciences Centre \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elgan Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elgan Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bronx Veterans Medical Research Foundation, Inc","sponsor":"VA Boston Healthcare System | Boston University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bronx Veterans Medical Research Foundation, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bronx Veterans Medical Research Foundation, Inc \/ VA Boston Healthcare System | Boston University","highestDevelopmentStatusID":"8","companyTruncated":"Bronx Veterans Medical Research Foundation, Inc \/ VA Boston Healthcare System | Boston University"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Undisclosed","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"CV-18C3","moa":"Interleukin-1 alpha","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Cl\u00ednica Universidad de Navarra","sponsor":"Sanofi | Hospital Universitario Infanta Leonor","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cl\u00ednica Universidad de Navarra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cl\u00ednica Universidad de Navarra \/ Sanofi | Hospital Universitario Infanta Leonor","highestDevelopmentStatusID":"8","companyTruncated":"Cl\u00ednica Universidad de Navarra \/ Sanofi | Hospital Universitario Infanta Leonor"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ PPD"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Undisclosed","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Revalesio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"RNS60","moa":"IntraCellular signaling","graph1":"Undisclosed","graph2":"Phase II","graph3":"Revalesio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Revalesio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revalesio \/ Undisclosed"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Iohexol","moa":"iodine-containing contrast media","graph1":"Undisclosed","graph2":"Phase II","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ligand Pharmaceuticals \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Yale University","sponsor":"National Institute on Drug Abuse | Office of Research on Women's Health | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ National Institute on Drug Abuse | Office of Research on Women's Health | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ National Institute on Drug Abuse | Office of Research on Women's Health | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Undisclosed","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raziel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alkahest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"GRF6021","moa":"Lysine gingipain","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alkahest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkahest \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ABT-719","moa":"Melanocortin receptor 1 | Melanocortin receptor 3","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Technological Centre of Nutrition and Health, Spain","sponsor":"Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | Plantas Medicinales y Complementos Alimenticios, S.A. | University Rovira i Virgili","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Technological Centre of Nutrition and Health, Spain","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Technological Centre of Nutrition and Health, Spain \/ Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | Plantas Medicinales y Complementos Alimenticios, S.A. | University Rovira i Virgili","highestDevelopmentStatusID":"8","companyTruncated":"Technological Centre of Nutrition and Health, Spain \/ Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | Plantas Medicinales y Complementos Alimenticios, S.A. | University Rovira i Virgili"},{"orgOrder":0,"company":"PISA","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Undisclosed","graph2":"Phase II","graph3":"PISA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PISA \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"PISA \/ Merck & Co"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"VB-201","moa":"Monocyte differentiation antigen CD14 | Toll-like receptor 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ALKS37","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alvimopan","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hartford Hospital \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Hartford Hospital \/ Merck & Co"},{"orgOrder":0,"company":"Spectrum Health - Lakeland","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Morphine Sulfate","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Spectrum Health - Lakeland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Health - Lakeland \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Health - Lakeland \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ ChromaDex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ ChromaDex, Inc"},{"orgOrder":0,"company":"KGK Science","sponsor":"Niagen Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ ChromaDex, Inc","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Elysium Health"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"HealthTech Connex Inc. | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ HealthTech Connex Inc. | Thorne HealthTech","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ HealthTech Connex Inc. | Thorne HealthTech"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sanford Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Sanford Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Sanford Health"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"HoHo Biotech","sponsor":"Taoyuan Armed Forces General Hospital | Tri-Service General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Hydrogen","moa":"None","graph1":"Undisclosed","graph2":"Phase II","graph3":"HoHo Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HoHo Biotech \/ Taoyuan Armed Forces General Hospital | Tri-Service General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"HoHo Biotech \/ Taoyuan Armed Forces General Hospital | Tri-Service General Hospital"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Whanin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Whanin Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Whanin Pharmaceutical"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Undisclosed"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"24-valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TS-142","moa":"Orexin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shalvata Mental Health Center","sponsor":"Clalit","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Shalvata Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Shalvata Mental Health Center \/ Clalit","highestDevelopmentStatusID":"8","companyTruncated":"Shalvata Mental Health Center \/ Clalit"},{"orgOrder":0,"company":"Shalvata Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Shalvata Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shalvata Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shalvata Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Shalvata Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Shalvata Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shalvata Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shalvata Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gefapixant Citrate","moa":"P2X purinoceptor 3","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Michigan \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"University of Michigan \/ Eli Lilly"},{"orgOrder":0,"company":"Centre Georges Fran\u00e7ois Leclerc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Undisclosed","graph2":"Phase II","graph3":"Centre Georges Fran\u00e7ois Leclerc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Georges Fran\u00e7ois Leclerc \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Centre Georges Fran\u00e7ois Leclerc \/ AstraZeneca"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ AstraZeneca"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sintilimab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"TQB2450","moa":"PD-L1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Royal DSM","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ Royal DSM"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Nico Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Maryland, Baltimore \/ Nico Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Nico Corporation"},{"orgOrder":0,"company":"Neothetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"LIPO-102","moa":"Phosphodiesterase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Neothetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neothetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neothetics \/ Undisclosed"},{"orgOrder":0,"company":"Inventprise","sponsor":"Canadian Center for Vaccinology | Vaccine Evaluation Center, Canada | PATH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IVT PCV-25","moa":"Pneumococcal polysaccharide antigens","graph1":"Undisclosed","graph2":"Phase II","graph3":"Inventprise","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inventprise \/ Canadian Center for Vaccinology | Vaccine Evaluation Center, Canada | PATH","highestDevelopmentStatusID":"8","companyTruncated":"Inventprise \/ Canadian Center for Vaccinology | Vaccine Evaluation Center, Canada | PATH"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Takeda Pharmaceutical | Korean Cancer Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Anam Hospital \/ Takeda Pharmaceutical | Korean Cancer Study Group","highestDevelopmentStatusID":"8","companyTruncated":"Korea University Anam Hospital \/ Takeda Pharmaceutical | Korean Cancer Study Group"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SAR279356","moa":"Poly-N-acetyl glucosamine (PNAG)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rabeprazole Sodium","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eisai \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai \/ Undisclosed"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Cuidado Integral de la Mujer, Gineclinic, S.C.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C.","highestDevelopmentStatusID":"8","companyTruncated":"Gynuity Health Projects \/ Cuidado Integral de la Mujer, Gineclinic, S.C."},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2010","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Agile Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Agile Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Levonorgestrel","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Agile Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agile Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Agile Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Theramex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Nomegestrol Acetate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Theramex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theramex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theramex \/ Undisclosed"},{"orgOrder":0,"company":"Health Decisions","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ulipristal Acetate","moa":"Progesterone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Health Decisions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Health Decisions \/ Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Health Decisions \/ Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"Institut Curie | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jules Bordet Institute \/ Institut Curie | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Jules Bordet Institute \/ Institut Curie | AstraZeneca"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Jiangsu Hengrui Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Camrelizumab","moa":"Programmed cell death protein 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Jiangsu Hengrui Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Jiangsu Hengrui Pharmaceutical"},{"orgOrder":0,"company":"Zhejiang Echon Biopharm Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Zhejiang Echon Biopharm Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Zhejiang Echon Biopharm Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Echon Biopharm Limited \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Echon Biopharm Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GB001","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Zhejiang Echon Biopharm Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray","sponsorNew":"Zhejiang Echon Biopharm Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Echon Biopharm Limited \/ Undisclosed"},{"orgOrder":0,"company":"Envisia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Envisia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Envisia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Envisia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Peplin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peplin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peplin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peplin \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Innovative Medicines Initiative | Antibacterial Resistance Leadership Group | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"MEDI3902","moa":"Psl | Low calcium response locus protein V","graph1":"Undisclosed","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Innovative Medicines Initiative | Antibacterial Resistance Leadership Group | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Innovative Medicines Initiative | Antibacterial Resistance Leadership Group | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Cipargamin","moa":"P-type ATPase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase II","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SFJ Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SFJ Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Undisclosed","graph2":"Phase II","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SFJ Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SFJ Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Diquafosol","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EDP-938","moa":"Respiratory syncytial virus protein N (RSV N)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EDP-938","moa":"Respiratory syncytial virus protein N (RSV N)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Enanta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Multispecialty Aesthetic Clinical Research Organization","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Multispecialty Aesthetic Clinical Research Organization","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Multispecialty Aesthetic Clinical Research Organization \/ Galderma","highestDevelopmentStatusID":"8","companyTruncated":"Multispecialty Aesthetic Clinical Research Organization \/ Galderma"},{"orgOrder":0,"company":"QLT Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Vitamin A Acetate","moa":"retinol derivatives","graph1":"Undisclosed","graph2":"Phase II","graph3":"QLT Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QLT Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"QLT Inc \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Royal DSM \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lumicitabine","moa":"RNA-directed RNA polymerase L","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lumicitabine","moa":"RNA-directed RNA polymerase L","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lumicitabine","moa":"RNA-directed RNA polymerase L","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dantrolene","moa":"Ryanodine receptor 3 | Ryanodine receptor 1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eagle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eagle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eagle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"PPD | Johns Hopkins University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ PPD | Johns Hopkins University","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ PPD | Johns Hopkins University"},{"orgOrder":0,"company":"Fundaci\u00f3n Hu\u00e9sped","sponsor":"Dalhousie University | CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ARGENTINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Ad5-nCov","moa":"SARS-CoV-2 S","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fundaci\u00f3n Hu\u00e9sped","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n Hu\u00e9sped \/ Dalhousie University | CanSino Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Fundaci\u00f3n Hu\u00e9sped \/ Dalhousie University | CanSino Biologics"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, mRNA","moa":"SARS-CoV-2 S||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ PPD"},{"orgOrder":0,"company":"GBG Forschungs GmbH","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Capivasertib","moa":"Serine\/threonine-protein kinase AKT","graph1":"Undisclosed","graph2":"Phase II","graph3":"GBG Forschungs GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GBG Forschungs GmbH \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"GBG Forschungs GmbH \/ AstraZeneca"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"MK2206","moa":"Serine\/threonine-protein kinase AKT","graph1":"Undisclosed","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TAK-954","moa":"Serotonin 4 (5-HT4) receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Fenfluramine HCl","moa":"Sigma opioid receptor | Serotonin 2c (5-HT2c) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Oleogel-S10","moa":"Skin barrier","graph1":"Undisclosed","graph2":"Phase II","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SINTETICA SA","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Chloroprocaine HCl","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase II","graph3":"SINTETICA SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"SINTETICA SA \/ Cross Research S.A.","highestDevelopmentStatusID":"8","companyTruncated":"SINTETICA SA \/ Cross Research S.A."},{"orgOrder":0,"company":"Tusker Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase II","graph3":"Tusker Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tusker Medical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tusker Medical \/ Undisclosed"},{"orgOrder":0,"company":"St. Renatus","sponsor":"Ground Zero Pharmaceuticals | Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tetracaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase II","graph3":"St. Renatus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Renatus \/ Ground Zero Pharmaceuticals | Rho Inc","highestDevelopmentStatusID":"8","companyTruncated":"St. Renatus \/ Ground Zero Pharmaceuticals | Rho Inc"},{"orgOrder":0,"company":"Juniper Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"COL-1077","moa":"Sodium channel unspecific (NaC)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Juniper Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Insert","sponsorNew":"Juniper Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Juniper Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Unity Health Toronto \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Swisse Wellness Pty Ltd","sponsor":"Swinburne University of Technology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Ginkgo","moa":"Sodium-dependent noradrenaline transporter; Phospholipase A2, membrane associated; Glycine receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit beta-2; Gamma-aminobutyric acid receptor subunit gamma-2; Amine oxidase [flavin-containing] A; Nitric oxide synthase, inducible","graph1":"Undisclosed","graph2":"Phase II","graph3":"Swisse Wellness Pty Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swisse Wellness Pty Ltd \/ Swinburne University of Technology","highestDevelopmentStatusID":"8","companyTruncated":"Swisse Wellness Pty Ltd \/ Swinburne University of Technology"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dotinurad","moa":"Solute carrier family 22 member 12","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Casirivimab","moa":"Spike glycoprotein","graph1":"Undisclosed","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Casirivimab","moa":"Spike glycoprotein","graph1":"Undisclosed","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ImmuneSensor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IMSA101","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Undisclosed","graph2":"Phase II","graph3":"ImmuneSensor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneSensor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmuneSensor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska \/ Amgen Inc"},{"orgOrder":0,"company":"Bonti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"EB-001","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bonti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bonti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bonti \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BMS-931699","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BMS-931699","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Sydney Local Health District","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bivalirudin","moa":"Thrombin","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sydney Local Health District \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sydney Local Health District \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Hormone","year":"2011","type":"Inapplicable","leadProduct":"Rovatirelin","moa":"Thyrotropin-releasing hormone receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PRT064445","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PRT064445","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PRT064445","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PRT064445","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PRT064445","moa":"Tissue factor pathway inhibitor | Apixaban | Rivaroxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Clinical Trials in Organ Transplantation | Rho, Inc | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Belatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation | Rho, Inc | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation | Rho, Inc | Bristol Myers Squibb"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Clinical Trials in Organ Transplantation | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation | Rho, Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Clinical Trials in Organ Transplantation | Rho, Inc"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Gencor Pacific Limited","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RDC Clinical \/ Gencor Pacific Limited","highestDevelopmentStatusID":"8","companyTruncated":"RDC Clinical \/ Gencor Pacific Limited"},{"orgOrder":0,"company":"Robert J. Pignolo","sponsor":"Genome Protection, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Peptide, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Undisclosed","graph2":"Phase II","graph3":"Robert J. Pignolo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Robert J. Pignolo \/ Genome Protection, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Robert J. Pignolo \/ Genome Protection, Inc."},{"orgOrder":0,"company":"National Heart, Lung, and Blood Institute","sponsor":"Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Heart, Lung, and Blood Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Heart, Lung, and Blood Institute \/ Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International","highestDevelopmentStatusID":"8","companyTruncated":"National Heart, Lung, and Blood Institute \/ Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International"},{"orgOrder":0,"company":"Stearacl Inc","sponsor":"Reinhold Vieth","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Menthol","moa":"Transient receptor potential cation channel subfamily A member 1 | Transient receptor potential cation channel subfamily M member 8","graph1":"Undisclosed","graph2":"Phase II","graph3":"Stearacl Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Stearacl Inc \/ Reinhold Vieth","highestDevelopmentStatusID":"8","companyTruncated":"Stearacl Inc \/ Reinhold Vieth"},{"orgOrder":0,"company":"Hokkaido University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hokkaido University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hokkaido University \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Hokkaido University \/ Merck & Co"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sheffield Teaching Hospitals NHS Foundation Trust","sponsor":"Amgen Inc | University of Sheffield","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Denosumab","moa":"Tumor necrosis factor ligand superfamily member 11","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sheffield Teaching Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sheffield Teaching Hospitals NHS Foundation Trust \/ Amgen Inc | University of Sheffield","highestDevelopmentStatusID":"8","companyTruncated":"Sheffield Teaching Hospitals NHS Foundation Trust \/ Amgen Inc | University of Sheffield"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"DynPort Vaccine Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"rF1V vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"DynPort Vaccine Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"DynPort Vaccine Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DynPort Vaccine Company \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zerun Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Shanghai Zerun Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zerun Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Zerun Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SCT1000","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"UMN Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ASP7373","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"UMN Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMN Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UMN Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Wenda Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"WD-890","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Zhejiang Wenda Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Wenda Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Wenda Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Wenda Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"WD-890","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Zhejiang Wenda Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Wenda Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Wenda Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"14-C FYU-981","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fuji Yakuhin \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Fuji Yakuhin \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"AdventHealth Translational Research Institute","sponsor":"BioTherapeutics Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abscisic Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AdventHealth Translational Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth Translational Research Institute \/ BioTherapeutics Inc.","highestDevelopmentStatusID":"8","companyTruncated":"AdventHealth Translational Research Institute \/ BioTherapeutics Inc."},{"orgOrder":0,"company":"Texas Enterosorbents Incorporated","sponsor":"Texas A&M University | University of Georgia | The University of Texas at San Antonio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ACCS100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Texas Enterosorbents Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Texas Enterosorbents Incorporated \/ Texas A&M University | University of Georgia | The University of Texas at San Antonio","highestDevelopmentStatusID":"8","companyTruncated":"Texas Enterosorbents Incorporated \/ Texas A&M University | University of Georgia | The University of Texas at San Antonio"},{"orgOrder":0,"company":"National Research Institute for Family Planning, China","sponsor":"Shanghai Jinxiang Latex Products Co.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acetic Acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Research Institute for Family Planning, China","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Research Institute for Family Planning, China \/ Shanghai Jinxiang Latex Products Co.","highestDevelopmentStatusID":"8","companyTruncated":"National Research Institute for Family Planning, China \/ Shanghai Jinxiang Latex Products Co."},{"orgOrder":0,"company":"KGK Science","sponsor":"Gencor Pacific Limited","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Activamp","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KGK Science \/ Gencor Pacific Limited","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Gencor Pacific Limited"},{"orgOrder":0,"company":"KGK Science","sponsor":"Standard Process Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"A-F Betafood","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KGK Science \/ Standard Process Inc.","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Standard Process Inc."},{"orgOrder":0,"company":"TBF Genie Tissulaire","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Amtrix-D","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"TBF Genie Tissulaire","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TBF Genie Tissulaire \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TBF Genie Tissulaire \/ Undisclosed"},{"orgOrder":0,"company":"Sutter Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Ashwagandha","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sutter Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutter Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sutter Health \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Covance | Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"At-III Human","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grifols International \/ Covance | Clinipace Worldwide","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Covance | Clinipace Worldwide"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Autologous Apheresis Platelet Component","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Dr. Soetomo General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Dr. Soetomo General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Bio Farma \/ Dr. Soetomo General Hospital"},{"orgOrder":0,"company":"Alume Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Bevonescein","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Alume Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alume Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alume Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"BLI4600","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BLI4900","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Schleswig-Holstein","sponsor":"Avextra | SocraMetrics GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cannabisextrakt Avextra L\u00f6sung","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University Hospital Schleswig-Holstein","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"University Hospital Schleswig-Holstein \/ Avextra | SocraMetrics GmbH","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Schleswig-Holstein \/ Avextra | SocraMetrics GmbH"},{"orgOrder":0,"company":"KGK Science","sponsor":"Lonza Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Carnipure","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Lonza Group"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Cognivida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2011","type":"Inapplicable","leadProduct":"Cognivida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Collagen Matrix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Collagen-Hydroxyapatite Scaffold","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Collagen Matrix","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Collagen Matrix"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Crystalline Lactulose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CSJ148","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CETYLITE INDUSTRIES","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CTY-5339","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"CETYLITE INDUSTRIES","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"CETYLITE INDUSTRIES \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CETYLITE INDUSTRIES \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CU-20401","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CU-20401","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CU-20401","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Franz K\u00f6hler Chemie GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Custodiol-N","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Dr. Franz K\u00f6hler Chemie GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dr. Franz K\u00f6hler Chemie GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Franz K\u00f6hler Chemie GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Lactalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Dairy Lipid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Lactalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lactalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lactalis \/ Undisclosed"},{"orgOrder":0,"company":"Dark Canyon Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DCL-101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Dark Canyon Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dark Canyon Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dark Canyon Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dilafor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DF 01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Dilafor AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dilafor AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dilafor AB \/ Undisclosed"},{"orgOrder":0,"company":"Pancap Pharma Inc.","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Digestive Enzyme Blend","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pancap Pharma Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pancap Pharma Inc. \/ Nutrasource","highestDevelopmentStatusID":"8","companyTruncated":"Pancap Pharma Inc. \/ Nutrasource"},{"orgOrder":0,"company":"Kosin University Gospel Hospital","sponsor":"Cell Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Duolac","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Kosin University Gospel Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kosin University Gospel Hospital \/ Cell Biotech Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Kosin University Gospel Hospital \/ Cell Biotech Co., Ltd."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Proteus | Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ECMPS-IEM","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Proteus | Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Proteus | Quintiles Inc"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ECP-019","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ColonaryConcepts \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Enterovirus Type 71 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Biotropics Malaysia Berhad","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Eurycomalongifoliawater Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Biotropics Malaysia Berhad","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Biotropics Malaysia Berhad"},{"orgOrder":0,"company":"Jiangsu Province Centers for Disease Control and Prevention","sponsor":"Beijing Vigoo Biological","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"EV71 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Province Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Province Centers for Disease Control and Prevention \/ Beijing Vigoo Biological","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Province Centers for Disease Control and Prevention \/ Beijing Vigoo Biological"},{"orgOrder":0,"company":"Jiangsu Province Centers for Disease Control and Prevention","sponsor":"Beijing Vigoo Biological","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"EV71 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Province Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Province Centers for Disease Control and Prevention \/ Beijing Vigoo Biological","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Province Centers for Disease Control and Prevention \/ Beijing Vigoo Biological"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ExPEC4V","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ExPEC4V","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ExPEC4V","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"FCN-338","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Fosun Pharmaceutical \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Flonoltinib","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Kaneka Americas Holding Inc.","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Floradapt Mature Immune Defense","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Kaneka Americas Holding Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Americas Holding Inc. \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Kaneka Americas Holding Inc. \/ KGK Science"},{"orgOrder":0,"company":"Resilience Government Services","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"G03-52-01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Resilience Government Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience Government Services \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Resilience Government Services \/ US Department of Defense"},{"orgOrder":0,"company":"Resilience Government Services","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"G03-52-01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Resilience Government Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience Government Services \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Resilience Government Services \/ US Department of Defense"},{"orgOrder":0,"company":"General Practitioners Research Institute","sponsor":"G3 Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"G3P-01","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"General Practitioners Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"General Practitioners Research Institute \/ G3 Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"General Practitioners Research Institute \/ G3 Pharmaceuticals"},{"orgOrder":0,"company":"German Center for Diabetes Research","sponsor":"Code Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Gammora","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"German Center for Diabetes Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Center for Diabetes Research \/ Code Pharma","highestDevelopmentStatusID":"8","companyTruncated":"German Center for Diabetes Research \/ Code Pharma"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Contract Research Organization Cromos Pharma | contract research organization K-Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"GamTBvac Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Contract Research Organization Cromos Pharma | contract research organization K-Research","highestDevelopmentStatusID":"8","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Contract Research Organization Cromos Pharma | contract research organization K-Research"},{"orgOrder":0,"company":"IRCCS San Raffaele","sponsor":"Indena","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Gingko Biloba Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"IRCCS San Raffaele","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS San Raffaele \/ Indena","highestDevelopmentStatusID":"8","companyTruncated":"IRCCS San Raffaele \/ Indena"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ginsana","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Ginsana","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Fuji Oil Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Glucodia","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Fuji Oil Co. Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Fuji Oil Co. Ltd."},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"GT101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"GT101","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GRIT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HR020602","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HR18034","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-9231","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Shengdi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Fujian Shengdi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fujian Shengdi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fujian Shengdi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HSK36273","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HSK36273","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Boehringer Ingelheim GmbH | CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Human Prothrombin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Boehringer Ingelheim GmbH | CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ Boehringer Ingelheim GmbH | CSL Behring"},{"orgOrder":0,"company":"University of Padova","sponsor":"Performa di Crocicchia Srl","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hyperbaric Oxygen","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Padova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Padova \/ Performa di Crocicchia Srl","highestDevelopmentStatusID":"8","companyTruncated":"University of Padova \/ Performa di Crocicchia Srl"},{"orgOrder":0,"company":"National Jewish Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Hypnotic Medication Taper","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Jewish Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Jewish Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"National Jewish Health \/ Undisclosed"},{"orgOrder":0,"company":"Inserm","sponsor":"MCM Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Inactivated Non Adjuvanted Pandemic H1N1 Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ MCM Vaccines","highestDevelopmentStatusID":"8","companyTruncated":"Inserm \/ MCM Vaccines"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Inactivated Poliomyelitis Vaccine (Sabin Strain)","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Infant Formula","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Infant Formula","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Infant Formula","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"NONOXYNOL-9","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Icosavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Undisclosed"},{"orgOrder":0,"company":"Icosavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"IVX-A12","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Thorne HealthTech | National Center for Complementary and Integrative Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Kava","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Florida \/ Thorne HealthTech | National Center for Complementary and Integrative Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ Thorne HealthTech | National Center for Complementary and Integrative Health"},{"orgOrder":0,"company":"University of Florida","sponsor":"National Center for Complementary and Integrative Health | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Kava","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Florida \/ National Center for Complementary and Integrative Health | Thorne HealthTech","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ National Center for Complementary and Integrative Health | Thorne HealthTech"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Kiddi Pharmaton Fizz","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Olympic Seafood AS","sponsor":"Oy Foodfiles Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Krill Oil","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Olympic Seafood AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Olympic Seafood AS \/ Oy Foodfiles Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Olympic Seafood AS \/ Oy Foodfiles Ltd"},{"orgOrder":0,"company":"Henry M. Jackson Foundation","sponsor":"TearSolutions | Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lacripep","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Henry M. Jackson Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Henry M. Jackson Foundation \/ TearSolutions | Walter Reed National Military Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Henry M. Jackson Foundation \/ TearSolutions | Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Biose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Lactobacillus Casei Rhamnosus","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Biose","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Biose \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biose \/ Undisclosed"},{"orgOrder":0,"company":"LG Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"LD02GIFRO","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"LG Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LG Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lument","sponsor":"Q Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Lumentin 44","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Lument","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Lument \/ Q Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Lument \/ Q Clinical"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Lumivida","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LY3549492","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY3549492","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"HemCon Medical Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lyophilized Plasma","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"HemCon Medical Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HemCon Medical Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HemCon Medical Technologies \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"The First Hospital of Jilin University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MB07133","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University","highestDevelopmentStatusID":"8","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ The First Hospital of Jilin University"},{"orgOrder":0,"company":"The Medicines Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"MDCO-2010","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"The Medicines Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The Medicines Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Medicines Company \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MHAA549A","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Metro International Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MIB 626","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Metro International Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metro International Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Metro International Biotech \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"MPB-1523","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"mPnC","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1893","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"mRNA-1893","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Moderna Therapeutics \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Medicus Research, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dimethyl Sulfone","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Medicus Research, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicus Research, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Research, LLC \/ Undisclosed"},{"orgOrder":0,"company":"CareFusion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"N,N\\'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"CareFusion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CareFusion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CareFusion \/ Undisclosed"},{"orgOrder":0,"company":"Lagos State Health Service Commission","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NIGERIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Lagos State Health Service Commission","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lagos State Health Service Commission \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lagos State Health Service Commission \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"NoV GI.1\/GII.4 Bivalent VLP Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NT100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nora Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NT100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nora Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nora Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nora Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Becton Dickinson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Becton Dickinson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Becton Dickinson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Becton Dickinson \/ Undisclosed"},{"orgOrder":0,"company":"Becton Dickinson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Octenidine Hydrochloride","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Becton Dickinson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Becton Dickinson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Becton Dickinson \/ Undisclosed"},{"orgOrder":0,"company":"Medicus Research, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Onion-Pumpkin Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Medicus Research, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicus Research, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Research, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Pharmaton","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Biotropics Malaysia Berhad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MALAYSIA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Phyllantus Amarus","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Biotropics Malaysia Berhad","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotropics Malaysia Berhad \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotropics Malaysia Berhad \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"POM Wonderful","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Ellagic acid","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ POM Wonderful","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ POM Wonderful"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"POM Wonderful","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Pomx","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, Los Angeles \/ POM Wonderful","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ POM Wonderful"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID19-B","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Providence Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PTX-COVID19-B","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Providence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Providence Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Providence Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Purified Inactivated Zika Virus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"PATH","sponsor":"Serum Institute of India | Agilis | Pharmassist | MCT-CRO | Cytespace","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"R21 Matrix-M Malaria Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"PATH \/ Serum Institute of India | Agilis | Pharmassist | MCT-CRO | Cytespace","highestDevelopmentStatusID":"8","companyTruncated":"PATH \/ Serum Institute of India | Agilis | Pharmassist | MCT-CRO | Cytespace"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RBT-1","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RemeGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RC108","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"RemeGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Undisclosed"},{"orgOrder":0,"company":"PharmaJet","sponsor":"National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human Papillomavirus Quadrivalent Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"PharmaJet \/ National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"PharmaJet \/ National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Recombinant Human Papillomavirus Quadrivalent Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Moffitt Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Red Blood Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerus Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerus Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Da-an Bio-technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Regan Tangjiang","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Beijing Da-an Bio-technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Da-an Bio-technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Da-an Bio-technology \/ Undisclosed"},{"orgOrder":0,"company":"Valexfarm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Remegal","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Valexfarm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valexfarm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Valexfarm \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"rLP2086","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"rLP2086","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"RO5093151","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"RO5093151","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rsv Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rsv Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Rsv Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"PATH","sponsor":"SK Bioscience | Murdoch Childrens Research Institute | Children's Hospital Medical Center, Cincinnati | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"RV3-BB","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ SK Bioscience | Murdoch Childrens Research Institute | Children's Hospital Medical Center, Cincinnati | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"PATH \/ SK Bioscience | Murdoch Childrens Research Institute | Children's Hospital Medical Center, Cincinnati | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sanfu Herbal","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAR445419","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Seasonal Trivalent Split, Inactivated Influenza Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Seresis","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Seresis","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Seresis","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Pharmasyntez","sponsor":"Cromos Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Seroguard","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pharmasyntez","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmasyntez \/ Cromos Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pharmasyntez \/ Cromos Pharma"},{"orgOrder":0,"company":"Pharmasyntez","sponsor":"Sciencefiles","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Seroguard","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pharmasyntez","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pharmasyntez \/ Sciencefiles","highestDevelopmentStatusID":"8","companyTruncated":"Pharmasyntez \/ Sciencefiles"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Wellcome Trust | Bill & Melinda Gates Medical Research Institute | Henry M. Jackson Foundation | Walter Reed Army Institute of Research | Parexel | ClinWin Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SF2A-TT15","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Pasteur \/ Wellcome Trust | Bill & Melinda Gates Medical Research Institute | Henry M. Jackson Foundation | Walter Reed Army Institute of Research | Parexel | ClinWin Research","highestDevelopmentStatusID":"8","companyTruncated":"Institut Pasteur \/ Wellcome Trust | Bill & Melinda Gates Medical Research Institute | Henry M. Jackson Foundation | Walter Reed Army Institute of Research | Parexel | ClinWin Research"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR7280","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR7280","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR7280","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"SRM003","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Stayble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"STA363","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Stayble Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stayble Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stayble Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Staphylococcus Aureus 4-Antigen SA4Ag Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Australian and New Zealand Intensive Care Research Centre","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Supplemental Parenteral Nutrition","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Australian and New Zealand Intensive Care Research Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Australian and New Zealand Intensive Care Research Centre \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Australian and New Zealand Intensive Care Research Centre \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"tOPV","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TP-05","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"Bharat Biotech | Wellcome Trust","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TSCV","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Maryland, Baltimore \/ Bharat Biotech | Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"University of Maryland, Baltimore \/ Bharat Biotech | Wellcome Trust"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"V0018","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VAX-24","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Undisclosed"},{"orgOrder":0,"company":"Vaxcyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VAX-31","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Vaxcyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxcyte \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaxcyte \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDONESIA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Vi-Dt Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Seoul St. Mary's Hospital","sponsor":"Health Biomed Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Y-75","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Seoul St. Mary's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul St. Mary's Hospital \/ Health Biomed Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Seoul St. Mary's Hospital \/ Health Biomed Inc."},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Zoster Vaccine Recombinant","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Colorado, Denver \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ GSK"},{"orgOrder":0,"company":"Swedish Medical Center","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Swedish Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Medical Center \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Swedish Medical Center \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apatinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Undisclosed","graph2":"Phase II","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking University People's Hospital \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Population Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Population Health Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Population Health Research Institute"},{"orgOrder":0,"company":"Gillette Children's Specialty Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Gabapentin","moa":"Voltage-gated calcium channel","graph1":"Undisclosed","graph2":"Phase II","graph3":"Gillette Children's Specialty Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gillette Children's Specialty Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gillette Children's Specialty Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Sodium Bicarbonate","moa":"Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Sodium Bicarbonate","moa":"Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Potassium Nitrate","moa":"Voltage-gated inwardly rectifying potassium channel KCNH2","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"South-Eastern Norway Regional Health Authority | University of Oslo","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ South-Eastern Norway Regional Health Authority | University of Oslo"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Health Decisions","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Health Decisions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Health Decisions \/ Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Health Decisions \/ Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"Brock Beauty Inc.","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Brock Beauty Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brock Beauty Inc. \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Brock Beauty Inc. \/ KGK Science"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Nicholas Macklon","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"HUNGARY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gedeon Richter \/ Nicholas Macklon","highestDevelopmentStatusID":"8","companyTruncated":"Gedeon Richter \/ Nicholas Macklon"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Fernanda P Silveira","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Undisclosed","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Fernanda P Silveira","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Fernanda P Silveira"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ National OncoVenture","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ National OncoVenture"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"David E Gerber","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tvb-2640","moa":"Fatty acid synthase (FASN)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sagimet Biosciences \/ David E Gerber","highestDevelopmentStatusID":"8","companyTruncated":"Sagimet Biosciences \/ David E Gerber"},{"orgOrder":0,"company":"KGK Science","sponsor":"Danisco","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase II","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KGK Science \/ Danisco","highestDevelopmentStatusID":"8","companyTruncated":"KGK Science \/ Danisco"},{"orgOrder":0,"company":"WCCT Global","sponsor":"Dance Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"WCCT Global","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"WCCT Global \/ Dance Biopharm","highestDevelopmentStatusID":"8","companyTruncated":"WCCT Global \/ Dance Biopharm"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Barry A. Boilson","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Undisclosed","graph2":"Phase II","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JANSSEN BIOTECH \/ Barry A. Boilson","highestDevelopmentStatusID":"8","companyTruncated":"JANSSEN BIOTECH \/ Barry A. Boilson"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"PD Dr. med. Volker Heinemann","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ PD Dr. med. Volker Heinemann","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ PD Dr. med. Volker Heinemann"},{"orgOrder":0,"company":"GSK","sponsor":"Moshe Yeshurun","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eltrombopag","moa":"Thrombopoietin receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Moshe Yeshurun","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Moshe Yeshurun"},{"orgOrder":0,"company":"medac","sponsor":"Prof. Dr. med. Wolfgang Bethge","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ Prof. Dr. med. Wolfgang Bethge","highestDevelopmentStatusID":"8","companyTruncated":"medac \/ Prof. Dr. med. Wolfgang Bethge"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR445419

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic ...

                            Details : SAR445419 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 14, 2023

                            Lead Product(s) : SAR445419

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Mount Sinai St. Luke’s and Mount Sinai West

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

                            Details : Onabotulinumtoxina is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 12, 2013

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Mount Sinai St. Luke’s and Mount Sinai West

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABT-719

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury i...

                            Details : ABT-719 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2013

                            Lead Product(s) : ABT-719

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            medac

                            Germany
                            CPhI WW Frankfurt
                            Booth #5.0B92
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Boothmedac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Prof. Dr. med. Wolfgang Bethge

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation A...

                            Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 20, 2012

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Prof. Dr. med. Wolfgang Bethge

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paritaprevir

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and W...

                            Details : Paritaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 25, 2011

                            Lead Product(s) : Paritaprevir

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SAR279356

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Vent...

                            Details : SAR279356 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 08, 2011

                            Lead Product(s) : SAR279356

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mayo Clinic

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metyrapone

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metyrapone Study for Patients Diagnosed with Mild Autonomous Cortisol Secretion - MACS

                            Details : Metyrapone is a Steroid drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 22, 2025

                            Lead Product(s) : Metyrapone

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eli Lilly

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LY3549492

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of LY3549492 in Healthy Weight Adult Participants

                            Details : LY3549492 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 25, 2025

                            Lead Product(s) : LY3549492

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jiangsu Hengrui Medicine

                            China arrow
                            SupplySide West
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remimazolam Tosilate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients

                            Details : Remimazolam Tosilate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 25, 2025

                            Lead Product(s) : Remimazolam Tosilate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of Oxford

                            United Kingdom arrow
                            SupplySide West
                            Not Confirmed

                            University of Oxford

                            United Kingdom arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 5-Aminolevulinic Acid HCl

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : SBI Pharmaceuticals Co, Ltd. | George Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment with 5-AminoLEvuliNic Acid Before Cardiac Surgery

                            Details : 5-Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2025

                            Lead Product(s) : 5-Aminolevulinic Acid HCl

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : SBI Pharmaceuticals Co, Ltd. | George Clinical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth